pradigastat: Clinical Trials

6 trials of pradigastat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 2
Phase 11Completed 1

Follow pradigastat: new trials by email Literature Review of pradigastat trials Research Report on pradigastat

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Proof of Concept Study of Pradigastat in Patients With Functional Constipation
Pradigastat Tablets 20mg, Pradigastat Tablets 40mg, Pradigastat Tablets 20mg matching Placebo - Functional Constipation
Phase 2CompletedAnji Pharma1812020-09-222022-08-24
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
LCQ908, placebo - Non-alcoholic Fatty Liver Disease (NAFLD)
Phase 2CompletedNovartis Pharmaceuticals522013-06-012016-02-04
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
LCQ908, Fenofibrate, Fish Oil - Non Familial Chylocmicronemia Syndrome (Non-FCS)
Phase 2CompletedNovartis Pharmaceuticals582012-06-012020-12-17
Efficacy of LCQ908 on Cardiovascular Risk
pradigastat (LCQ908), Placebo - Coronary Artery Disease, Hypertriglyceridemia
Phase 2TerminatedNovartis Pharmaceuticals412011-12-012016-04-14
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
LCQ908, Placebo - Hepatitis C
Phase 2TerminatedNovartis Pharmaceuticals322011-07-012012-05-08
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
LCQ908, Placebo - Hyperlipoproteinemia
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals82010-05-012020-12-17

Conditions studied

Hypertriglyceridemia (4)  ·  Coronary Artery Disease (1)  ·  Hepatitis C (1)  ·  Hyperlipidemias (1)  ·  Hyperlipoproteinemia Type I (1)  ·  Hyperlipoproteinemias (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Novartis Pharmaceuticals (5)  ·  Anji Pharma (1)

Countries

United States (4)  ·  Canada (2)  ·  China (1)  ·  New Zealand (1)  ·  Russia (1)

Top investigators

Dan Meyers, M.D. (1)

Results publications

PMID 25889044, PMID 27788579